Evidence map›Paper›PMID 41546023›Full record

ArticleJournal of nanobiotechnology2026

Low-dose X-ray-activated radiodynamic therapy via a lutetium-coordinated nanoplatform synergizing PARP inhibition and ferroptosis.

Wanli Song, Chuanyi Zhao, Youqing Mai, Guangrong Zhang, Wenyue Kang, Xuanjun Zheng, Qingpeng Yuan, Zeyang Chen, Chengxun Zhong, Junbao Tang and 4 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wanli Song *Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Chuanyi Zhao *Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Youqing Mai *Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Guangrong ZhangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Wenyue KangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Xuanjun ZhengDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Qingpeng YuanDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Zeyang ChenDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Chengxun ZhongDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Junbao TangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Duoyi FuDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Tiantian ZhaiDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Kai LingDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China. kailing@stu.edu.cn.
Hongyan JiangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China. hyjiang@stu.edu.cn.

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515030272Guangdong Basic and Applied Basic Research Foundation 2024A1515220028, and 2025A1515012054Li Ka Shing Foundation STU-GTIIT Joint-Research Grant 2024LKSFG03
6 · The paper itself

Abstract

Low-dose X-ray-activated radiodynamic therapy (RDT) is a promising strategy for precision oncology. However, its therapeutic efficacy is limited by tumor radioresistance and insufficient generation of reactive oxygen species (ROS). Here, we describe a biomimetic lutetium-coordinated black phosphorus nanosheet platform (BPNS@Lu

Indexed as

FerroptosisLutetiumPoly(ADP-ribose) Polymerase InhibitorsAnimalsCell Line, TumorHumansMicePhosphorusReactive Oxygen SpeciesX-RaysLutetiumPhosphorusPoly(ADP-ribose) Polymerase InhibitorsReactive Oxygen SpeciesBlack phosphorusFerroptosisHigh-Z metal elementsRadiodynamic therapyReactive oxygen species

Identifiers

PMID41546023
PMCPMC12892532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.